Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-6916 with Diltiazem
NCT06818968Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MK-6916 in pain, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity of MK-6916 up to 8 weeks, Area Under the Concentration-Time Curve from Time 0 to 24 hours of MK-6916 and 7 more. Started Feb 2025; status: completed.
02
Drugs
MK-6916
03
Conditions
pain
Beyond the preview
Go deeper on NCT06818968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818968.